ANGO icon

AngioDynamics

9.58 USD
+0.06
0.63%
At close Apr 29, 4:00 PM EDT
Pre-market
9.50
-0.08
0.84%
1 day
0.63%
5 days
0.84%
1 month
2.02%
3 months
-23.11%
6 months
38.04%
Year to date
6.68%
1 year
64.60%
5 years
-12.83%
10 years
-42.57%
 

About: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Employees: 748

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,056% more call options, than puts

Call options by funds: $2.58M | Put options by funds: $223K

21% more capital invested

Capital invested by funds: $250M [Q3] → $302M (+$52.6M) [Q4]

21% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 43

2.9% more ownership

Funds ownership: 79.06% [Q3] → 81.96% (+2.9%) [Q4]

3% less funds holding

Funds holding: 137 [Q3] → 133 (-4) [Q4]

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
67%
upside
Avg. target
$16
67%
upside
High target
$16
67%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
31% 1-year accuracy
53 / 171 met price target
67%upside
$16
Buy
Maintained
7 Apr 2025

Financial journalist opinion

Based on 9 articles about ANGO published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
Positive
Zacks Investment Research
2 weeks ago
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
Positive
Zacks Investment Research
3 weeks ago
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
Positive
Benzinga
3 weeks ago
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
Neutral
Seeking Alpha
3 weeks ago
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Eduardo Martinez - H.C. Wainwright Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call.
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
Positive
Zacks Investment Research
4 weeks ago
AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates
AngioDynamics (ANGO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.16 per share a year ago.
AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates
Neutral
Business Wire
4 weeks ago
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sale.
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
Neutral
Business Wire
4 weeks ago
AngioDynamics to Host Virtual Cardiovascular Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which wil.
AngioDynamics to Host Virtual Cardiovascular Investor Event
Neutral
Business Wire
1 month ago
AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into th.
AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event
Charts implemented using Lightweight Charts™